38.28

0.50% 0.19

Xenon Pharmaceuticals Inc (XENE)

Overview News Price History Option Chain Financials Discussions Forecast

Xenon Pharmaceuticals Inc stock is traded at $38.28, with a volume of 1.06M. It is up +0.50% in the last 24 hours and up +21.68% over the past month. Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Previous Close:

$38.09

Open:

$38

24h Volume:

1.06M

Relative Volume:

1.68

Market Cap:

$2.88B

Revenue:

$13.17M

Net Income/Loss:

$-199.06M

P/E Ratio:

-13.97

EPS:

-2.74

Net Cash Flow:

$-156.53M

1W Performance:

+1.75%

1M Performance:

+21.68%

6M Performance:

-8.18%

1Y Performance:

-10.98%

1-Day Range:

$37.74

$38.96

1-Week Range:

$36.94

$39.01

52-Week Range:

$26.74

$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name

Xenon Pharmaceuticals Inc

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

(604) 484-3300

Address

200 - 3650 GILMORE WAY, BURNABY

Employee

327

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

XENE's Discussions on Twitter

Compare XENE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XENE Xenon Pharmaceuticals Inc	38.28	2.88B	13.17M	-199.06M	-156.53M	-2.74
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jan-04-24	Initiated	Citigroup	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight
Dec-14-22	Initiated	Goldman	Buy
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight
Oct-19-22	Initiated	Raymond James	Outperform
Aug-29-22	Initiated	BofA Securities	Buy
Jul-21-22	Initiated	JP Morgan	Overweight
Oct-28-21	Initiated	RBC Capital Mkts	Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Jul-21-20	Initiated	Needham	Buy
Jun-01-20	Resumed	Jefferies	Buy
Mar-25-20	Initiated	Wedbush	Outperform
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy
Aug-08-18	Reiterated	Stifel	Buy
Mar-13-17	Initiated	Jefferies	Buy
Oct-21-16	Initiated	Stifel	Buy
Sep-26-16	Initiated	Guggenheim	Buy
Apr-14-16	Reiterated	Jefferies	Buy
Oct-30-15	Resumed	Jefferies	Buy
Dec-02-14	Initiated	Canaccord Genuity	Buy

View All

Xenon Pharmaceuticals Inc Stock (XENE) Latest News

May 02, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE Stock News - GuruFocus

May 02, 2025

Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks

May 02, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 02, 2025

Xenon Pharmaceuticals Expands Team with $3M Equity Package: 78,600 Options Granted to New Hires - Stock Titan

May 02, 2025

This trade activity should not be overlooked: Xenon Pharmaceuticals Inc (XENE) - Sete News

May 02, 2025

May 01, 2025

Upward Trajectory: Xenon Pharmaceuticals Inc (XENE) Posts a Slidee, Closing at 38.20 - DWinneX

May 01, 2025

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - Defense World

May 01, 2025

Apr 30, 2025